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Summary
The purpose of this paper is to present SARS-CoV-2 diagnostic methods and their optimal implementation. The 
main routine microbiological diagnostic tools are molecular and serological methods. Sensitivity and utilisation of 
molecular methods is the best at the disease onset, while serological methods are the best if used at least 5-7 days 
after disease onset. Positive molecular test result (real-time polymerase chain reaction; RT-PCR) must be interpreted 
in the clinical presentation context. A sampling site for molecular analysis is based on disease severity; upper and 
lower respiratory tract samples are used for mild and severe presentations, respectively. Virus cultivation is the only 
method of proving the existence of a viable virus in a tissue sample, but due to the method complexity, it is not a 
part of a routine process. Ground glass opacities with or without reticular pattern and/or consolidation are typical 
findings for COVID-19 pneumonia. Multi-slice computerized tomography (MSCT) is a superior radiological method 
for performing X-ray of the chests.
Sažetak
Ovaj članak ima za cilj prikazati dijagnostičke metode SARS-CoV-2 infekcije, kao i njihovu optimalnu primjenu. 
Glavne rutinske mikrobiološke dijagnostičke postupke predstavljaju molekularne i serološke metode. Osjetljivost 
i primjena molekularnih metoda najbolja je na početku bolesti, dok je primjena seroloških metoda najprikladnija 
barem 5-7 dana nakon početka bolesti. Pozitivan rezultat molekularnog testa (lančana reakcija polimeraze u 
stvarnom vremenu, engl. real-time polymerase chain reaction; RT-PCR) mora biti protumačen u skladu s kliničkom 
prezentacijom. Mjesto uzorkovanja za molekularnu analizu ovisi o težini bolesti; uzorci iz gornjeg i donjeg respi-
ratornog trakta koriste se pri blagim i teškim prezentacijama, navedenim redoslijedom. Uzgoj virusa na staničnoj 
kulturi jedina je metoda koja se primjenjuje u svrhu dokazivanja živog virusa u uzorku tkiva, međutim, metoda se 
ne izvodi rutinski zbog složenosti metodologije. Promjene po tipu mliječnog stakla s ili bez retikularnog uzorka 
i/ili konsolidacija tipične su pojave kod COVID-19 upale pluća. Višeslojna kompjutorizirana tomografija (engl. 
multi-slice computerized tomography; MSCT) predstavlja superiornu metodu, u odnosu na klasični RTG srca i pluća.
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 In December 2019, a novel Coronavirus was iden-
tified as the cause of a cluster of pneumonia cases in 
Wuhan, China. Over the following months, it has rap-
idly been spreading across the globe, causing the big-
gest pandemic of the 21st century. The virus was named 
SARS-CoV-2 (Severe Acute Repiratory Syndrome 
Coronavirus-2), while the disease was named COV-
ID-19 (Coronavirus Disease 2019). At the moment 
of writing this article, it has infected over 24.000.000 
individuals and caused more than 800.000 fatali-
ties worldwide, of which nearly 2.000.000 cases and 
180.000 deaths belong to the European Union/Euro-
pean Economic Area and the United Kingdom (UK)[1]. 
The medical and scientific community are witnessing 
a worldwide collaborative effort in understanding the 
virus and the disease, with hundreds of new scientific 
publications being available daily, thus expanding on 
knowledge concerning the spread of the virus and its 
effects on individuals and society. Little is known con-
cerning the period of infectiousness, persistence and 
efficiency of long-term immunity, while the targeted 
treatment and vaccines are not yet available and are 
thus a subject of intensive research. The focus of this 
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are used in more severe clinical presentations. The se-
rological methods are supplementary since they can 
generally be used 5-7 days after the symptoms onset, 
due to the dynamics of immune response and anti-
bodies production. The serological methods can be 
used when molecular test results are inconclusive, in 
addition to being a useful indicator of the previous in-
fection. ECDC does not recommend making the diag-
nosis of acute infection solely by applying serological 
methods[4]. Virus isolation in a cell culture is a definite 
proof of a viable virus presence, but due to a complex 
and long-lasting procedure, it is not appropriate for a 
routine use on a large number of samples. Another less 
utilized method of COVID-19 diagnostics is antigen 
detection. It uses the same specimens as molecular 
methods, but its advantages are rapid availability of re-
sults and point-of-care diagnosis. Even though it has 
a specificity of more than 99%, it is not used routinely 
due to the sensitivity of only 55% in comparison with 
molecular methods[5].
Molecular Diagnostics
 The basis of diagnosing acute SARS-CoV-2 infec-
tion is the detection of viral RNA in clinical samples by 
conducting nucleic acid amplification tests (NAAT), 
most commonly reverse transcription polymerase 
chain reaction (RT-PCR). Several in-house protocols 
have been developed. The protocols, most commonly 
used in Europe, test the presence of the Envelope (E) 
gene used for SARS-CoV-2 screening and RNA-de-
pendent RNA polymerase (RdRp) gene used for con-
firmation. The other most common target genes in 
various protocols include the Nucleocapsid (N) and 
Open reading frame 1 (Orf1) gene[6]. At the pandemic 
onset, the WHO and other agencies recommended at 
least two independent targets to be positive for declar-
ing a person infected with SARS-CoV-2 due to public 
health implications. With confirmed autochthonous 
cases within a country, a single positive target is con-
sidered enough. NAATs are considered highly specific 
and sensitive, even though various protocols differ in 
their sensitivity up to a 1000-fold[7]. Additional factors 
influencing sensitivity include a type of clinical spec-
imen, the timing of specimen sampling, viral load, 
patient’s characteristics, disease severity, sampling 
technique, sample transportation, storage and analy-
sis methods. The most common samples for RT-PCR 
confirmation of viral presence are upper and lower 
respiratory tract swabs and specimens, although viral 
RNA has also been detected in blood, urine and faeces.
Cycle threshold (Ct) is the number of reaction cycles in 
real-time PCR, required to obtain a fluorescent signal 
and it is inversely correlated with viral load in samples; 
article is a narrative review of COVID-19 diagnostic 
methods with special attention devoted to relationship 
and clinical implications of specimen type, the tim-
ing of sampling, viral load, duration of viral shedding, 
disease severity, patient characteristics and kinetics of 
sample positivity.
Epidemiology and Clinical Presentation
 Disease severity ranges from asymptomatic and 
mild to critical and fatal. According to data from the 
Chinese CDC, gathered from 44.500 confirmed infec-
tions, 81% of cases are mild (no or mild pneumonia), 
14% severe (dyspnea, hypoxia, more than 50% of lung 
involvement on imaging with 24-48 hours) and 5% 
critical (respiratory failure, shock, dysfunction of mul-
tiple organs). Overall case fatality rate is 2.3%; 14.8% 
in patients aged 80 or more, 8.0% in patients aged 70-
79 and 49.0% in critical cases[2]. ECDC reports that 
28% of all COVID-19 cases in the European Economic 
Area and the UK were hospitalized (median age 57), 
while 14% of hospitalized patients required intensive 
care and/or respiratory support (median age 64). It is 
estimated that 24% of hospitalized patients died, and 
almost all of them were aged 60 or more[1].
Diagnosis
 According to the WHO guidelines, any patient 
with a new onset of fever and/or respiratory symptoms 
should be considered as a patient suffering from acute 
SARS-CoV-2 infection and specific microbiological 
diagnostics is needed for confirmation. Infection is 
more probable, if there is no alternate diagnosis ex-
plaining clinical features in details, if the patient trav-
elled to an area with a high rate of local SARS-CoV-2 
transmission or if the patient had close contact with 
confirmed or suspected case of COVID-19 in the last 
14 days[3].
 Currently, the diagnosis of SARS-CoV-2 infection 
can be established by using molecular and serological 
tests. Although not used routinely, virus isolation in 
cell culture is another valuable diagnostic method. 
Molecular diagnostic method is the most widely used 
method due to high sensitivity during pre-sympto-
matic and the first few symptomatic days, speed and 
procedure simplicity. However, since molecular meth-
ods can only verify the presence of viral nucleic acid, 
a positive test does not necessarily mean the presence 
of a viable virus. Therefore, the test results are to be 
interpreted in the clinical presentation context. ECDC 
guidelines recommend molecular testing of the upper 
respiratory tract specimens for diagnosing acute in-
fection in individuals with symptoms consistent with 
COVID-19[4]. The lower respiratory tract specimens 
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protective equipment. The sensitivity of the method is 
100%, specificity 95%, but the study included only 30 
patients, while the method of sample collection was 
not described in detail[13].
 Based on this data, several observations can be 
made. The probability of RNA detection in an upper 
respiratory tract sample appears to be the highest if pa-
tients present it during the first week of symptomatic 
disease, it declines rapidly for mild cases and gradually 
for severe cases in the following weeks. Nasopharynge-
al swab has a high detection rate during the first week 
of the disease, and although oropharyngeal swab has 
somewhat lower detection sensitivity, both sites are 
easy to sample, and the detection sensitivity increases 
when combining both site samples in the same patient. 
Although sputum proved to be the specimen with the 
highest detection sensitivity along with a steady de-
cline rate throughout the disease course, currently it 
is not a recommended sample for routine use because 
the majority of patients do not produce sputum and 
cough induction for sputum production is not advis-
able. Nevertheless, the lower respiratory tract samples 
are used for diagnosing the severe cases and the result 
can be positive, even in later disease stages. It is worth 
noting that the patients with high clinical and radio-
logical suspicion and negative PCR test should be iso-
lated and retested, while the serological investigations 
should also be considered in these patients. Repeated 
testing (up to three times) increases the positivity rate 
up to 12%, from 85.9% to 97.5%, while retesting be-
yond the third time does not yield a significant rate in-
crease. The patients with initially positive samples are 
more likely to have or progress to severe disease[14, 15]
Implications of Viral Load in Samples
 Generally speaking, the rates of the positive respira-
tory tract samples can be correlated to viral loads, and 
the comparison can be performed between mild and 
severe presentation groups. Most studies show that 
viral loads of inpatients with mild disease are at their 
peak during the first or second week of the disease, af-
ter which they gradually decline, while some observed 
consistent load during the first three weeks of the dis-
ease[10, 11, 16-18]. The viral loads in the lower respiratory 
tract specimens of severe cases are initially higher than 
in mild cases and remain high throughout the disease 
course[10, 11, 16]. Some studies observed no difference of 
viral loads in the upper respiratory tract samples of 
mild and severe cases, but did observe significantly 
higher viral loads in older patients[16, 19]. Hu et al. an-
alysed the rate of negative conversion in patients with 
Ct values below 30 and 30 or above during the first 
three weeks of the disease and found no difference be-
tween the two groups, but found that chest tightness 
the lower Ct value number, the greater the quantity of 
viral RNA. Generally, the values below the threshold 
of Ct=38 are considered positive but depend upon 
implementation and validation of each assay in each 
laboratory. Due to this and because the sample quan-
tity varies with each individual swab of the respiratory 
tract, Ct is a highly variable and incomparable value.
Sampling Time Point and Sample Choice
 It is considered that detectable viral shedding be-
gins 1-2 days prior to the symptoms onset, however, 
Arons et al.[8] detected and isolated the virus in upper 
respiratory tract specimens 6 days prior to the symp-
toms onset. It should be noted that the participants 
were nursing home patients, and possible reasons for a 
long duration of RNA detection prior to the symptoms 
onset could be a small infectious dose, an alternate 
mode of virus entrance into organism or immunose-
nescence. Further validation requires studies observ-
ing suspected individuals in the general population.
Since COVID-19 primarily affects the respiratory sys-
tem, the most common samples for routine testing of 
suspected individuals are oropharyngeal and naso-
pharyngeal swabs. Several studies demonstrated high-
er sensitivity of nasopharyngeal swabs, while studies 
that sampled both sites simultaneously revealed low 
detection consistency between the two sites, but high-
er overall detection sensitivity[9, 10].
 According to data obtained by several studies[9-12], 
Table 1 represents rates of PCR positive respiratory 
specimens of mild and severe inpatients during the 
first 4 weeks of disease. The positive samples rates of 
both mild and severe cases are highest in the first week 
and have similar values, but in the following weeks, se-
vere cases positive rates show a more gradual decline 
than mild cases rates. Oropharyngeal swab rates show 
a more rapid decline, while nasopharyngeal swab rates 
exhibit a more gradual decline[9, 10, 12]. The combined 
positive rate of nasopharyngeal and oropharyngeal 
swabs is overall higher than rates of individual sites, 
most likely due to a previously described low level of 
consistency between the two sites. The combined pos-
itive rate of saliva (upper respiratory tract specimen) 
and sputum (lower respiratory tract specimen) speci-
mens is higher than individual rates of upper and low-
er respiratory tract specimens, also most likely due to a 
low level of consistency between the sites. The rates of 
positive samples from the lower respiratory tract (spu-
tum, bronchoalveolar lavage fluid - BALF) during the 
first 4 weeks are higher than the rates of samples from 
the upper respiratory tract. Another sample for diag-
nosing COVID-19 is a self-collected lower nasal swab, 
and its advantages are reduced risk of health care per-
sonnel virus exposure and reduced usage of personal 
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severe spectrum of disease, therefore the duration of vi-
ral shedding could be overestimated, as outpatients with 
mild disease were not periodically sampled.
Alternative Samples for SARS-CoV-2 Detection
There is evidence of faecal shedding of SARS-CoV-2. 
Zheng et al.[11] detected the virus in 59% of stool sam-
ples, and found that no difference in shedding between 
mild and severe cases. However, faecal shedding inten-
sified from the second week and the duration of vi-
rus detection in the stool is longer than the detection 
in respiratory samples (22 vs. 18 days) [Table 1]. In a 
study of 84 confirmed COVID-19 hospital workers 
with mild disease, 31% had diarrhoea, the mean time 
for throat swab to turn negative lasted longer than in 
the non-diarrhoea group (12.5 vs. 9.2 days) and they 
had a higher percentage of positive control stool sam-
ples, although the difference was not significant (45% 
vs. 20%)[21]. Although SARS-CoV-2 RNA can be de-
tected in stool, there is no clear evidence of the fae-
cal-oral route of transmission.
 Wolfel and Kujawski detected no RNA in the blood 
of mildly and moderately ill patients in their studies 
of 9 and 12 patients, respectively[17, 18]. Other studies 
report rates of RNA detection in the blood to be 15-
66% for mild patients and 30-87.5% for severe patients 
with low values of viral load[11, 16, 20]. To the best of our 
knowledge, no study reported successful virus isola-
tion from the blood. Several other bodily fluids were 
tested for the presence of viral RNA but only anecdotal 
evidence exists for the presence of RNA in urine and 
tears[11, 16-20].
Virus Cultivation
 Virus cultivation in a cell culture is the only meth-
od which can prove whether the virus in a sample is 
still viable. Although this information could warrant 
prolongation or discontinuation of patient isolation, the 
method is complex, long-lasting, and the performing 
laboratory must meet Biosafety Level 3 requirements. 
Due to these issues, it is not appropriate for routine use 
on a large number of samples and is primarily used for 
research purposes. Virus cultivation from the upper 
respiratory tract specimens was studied in relation to 
disease day by several research groups. Arons et al.[8] 
isolated the virus from the samples taken from 6 days 
before to 9 days after the symptoms onset, Kujawski et 
al.[17] from specimens taken before prior to day 9 and 
Wolfel et al.[18] from specimens taken before prior to day 
8. The unpublished data suggest that the virus isolation 
was not successful after day 10 in mild and moderate 
disease presentation, while the patients with a severe 
presentation rarely shed infectious virus up to day 20[22]. 
Based on these findings, the necessity of using person-
leads to longer conversion time[19]. To the best of our 
knowledge, this is the only study directly investigating 
the link between viral load and duration of RNA de-
tection in samples. In clinical practice, measuring viral 
loads in lower respiratory tract samples (i.e. sputum) 
could be helpful to discriminate patients requiring 
close monitoring and early antiviral treatment. How-
ever, most of the studies do not report exact values of 
viral loads, or do so in incomparable units of measure 
(log, number of virus copies per millilitre of sample 
and Ct values).
Nucleic Acid Detection Duration
 At the pandemic onset, in order to discharge a pa-
tient from hospital the symptoms must have been re-
solved and two consecutive swabs negative. However, 
several studies report the third swab to be positive in 
7-30% of the patients[9, 12, 19]. There has been no clear 
connection between this phenomenon and other pa-
rameters such as viral load, duration of positive sam-
ples or disease severity. It is unclear whether these 
patients shed infectious live virus, virions encircled 
by antibodies, viral nucleic acid, whether the test de-
tects infected epithelial cells or the test results are false 
positive. With a highly sensitive method like real-time 
PCR, this – most likely – represents the remnants of 
viral replication still being detected even though there 
is no active virus production. Such observations were 
made for this method in other viral diseases as well, 
but were not considered problematic, since no quar-
antine was required. These issues further question du-
ration of hospital stay, isolation and the potential for 
virus spreading from an individual with the two neg-
ative and subsequently positive samples after disease 
resolution.
 Conflicting data exist on the duration of RNA de-
tection in mild and severe cases. While some studies 
report median detection duration in the upper respira-
tory tract samples of mild cases to be 13-15 days[19, 20], 
the others report it to be 20-24 days[9, 12]. The latter du-
ration is similar to the reported median detection du-
ration of 21-22 days in both upper and lower respira-
tory tract samples of the severe cases[11, 20]. Although 
Zheng et al. found that RNA detection lasts longer in 
severe cases, To et al. found no correlation[11, 16]. Some 
patients' samples remain PCR positive even for a to-
tal of 5 weeks[12, 17, 18]. Several studies suggest that older 
patients have a prolonged period of virus elimination, 
possibly due to the immunosenescence, even though 
different age is reported as the threshold, from 45 to 
more than 65 years of age[9, 11, 12, 19]. Viral detection is 
also prolonged in patients who received glucocorticoids 
and in patients with comorbidities[11, 12]. All data were 
collected only from inpatients, who represent the more 
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There are several methods for antibodies detection in 
serum samples. The classic solid-phase enzyme-linked 
immunosorbent assays (ELISA) have relatively high 
sensitivity and specificity, chemiluminescence immu-
noassay methods (CLIA) have comparable character-
istics and lateral flow immunochromatographic assays 
(ICA) are affordable and easy to use, thus suitable for 
point of care testing. It is necessary to possess knowl-
edge of the method’s sensitivity and specificity, as well 
as its positive and negative predictive values while in-
terpreting results.
 According to antibody kinetics data from several 
studies, IgM and IgA antibodies are the early-stage 
markers. They appear towards the end of the first dis-
ease week, reach peak values in the second week and 
start to decline somewhere between the third and the 
fourth week. The IgG antibodies start to appear faint-
ly in the first week, continue to increase in quantity 
throughout the third week and reach the plateau by 
the end of it[24-28] [Table 2]. Padoan et al.[29] compared 
the IgA and IgM levels in PCR confirmed COVID-19 
patients and found persistently higher levels of IgA 
during the whole observation period with a peak lev-
el at days 20–22. To et al.[16] found the rate of the IgG 
positive samples to be higher than the rate of the IgM 
positive samples (94-100% vs 88-94%) 14 days after 
symptoms onset and Long et al.[24] found 100% of sam-
ples are IgG positive on days 17-19, while only 94.1% 
of samples are IgM positive on days 20-22. In compar-
al protective equipment could be reconsidered in these 
patients. The apparent correlation between the absence 
of specific antibodies and successful viral isolation may 
suggest the appearance of IgG antibodies in the serum 
as a possible time point for discharge of patients[18].
Serological Diagnostics
 Due to a variable sensitivity of molecular methods 
during the course of COVID-19, the serological meth-
ods have been investigated as a possible supplement. 
Generally speaking, the IgM and IgG antibodies are 
considered to be the markers of acute and past infection, 
respectively. The IgA antibodies, in addition to being the 
acute infection markers, are also the mucosal immuni-
ty and respiratory tract infection markers. The serolo-
gy sensitivity depends on host immune response, the 
timing of serum sampling, analysis method and assay 
quality, all of which vary among the manufacturers. The 
specificity depends on the type of antigen used for anti-
bodies detection. Surface spike protein (S), its subunit 
receptor-binding domain (RBD) and internal nucleop-
rotein (NP) are the most common protein antigens used 
in detection of antibodies against SARS-CoV-2. The 
studies found almost no N protein antibody cross-re-
activity of SARS-CoV-2 and other 4 human corona vi-
ruses, but found strong cross reactivity with SARS-CoV 
antibodies, possibly due to 90.5% sequence homolo-
gy. Nevertheless, RBD is specific to SARS-CoV-2 and 
should therefore be used for a higher specificity[16, 23].
Table 1. Rates of SARS-CoV-2 PCR positive samples in inpatients according to specimen site, disease severity and sam-
pling time.
Tablica 1. Stope uzoraka pozitivnih na SARS-CoV-2 metodom polimeraze lančane reakcije (PCR), podijeljene prema 
mjestu i vremenu uzorkovanja te težini bolesti.
Disease severity 
Sample
PCR positive sample rates (%)
Week 1 Week 2 Week 3 Week 4
Severe Mild Severe Mild Severe Mild Severe Mild
Nasopharyngeal 
























Sputum 89 82 83 74 61 43
Bronchoalveolar 
lavage fluid / / 100 0 78 / / /
Stool 44+ 29+ 47+ 50+ 41+ 59+ 31+ 56+
Unmarked data by Yang et al. (10); 
* - data by Xiao et al. (9) represents combined nasopharyngeal and oropharyngeal sample results of mild cases; 
+ - data by Zheng et al. (11) represents combined sputum and saliva samples and stool specimens’ results of mild and severe cases; 
∞ - data by Xiao et al. (12) represents combined nasopharyngeal and oropharyngeal sample results of mild cases.
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 In conclusion, the serological methods are an im-
portant supplement in COVID-19 diagnosis. Their 
sensitivity is at its peak when used 5 days after the 
disease onset, both independently or in conjunction 
with molecular methods. Serology is useful in distin-
guishing whether the patient is infected when clinical 
suspicion is high and molecular test is negative, and 
in situations when two or more molecular tests yield 
opposing results. It is yet unknown whether the IgG 
antibodies provide long-term immunity to an infect-
ed person. The serological methods utilisation also 
includes the asymptomatic cases detection, seroprev-
alence studies, detection of patients with convalescent 
serum for a potential use as therapy and monitoring of 
immune response to trial vaccines.
Radiological Diagnostics
 The imaging modalities used in SARS-CoV-2 in-
fection diagnosis are: chest x-ray (CXR), multi-slice 
computerized tomography (MSCT) imaging and 
lungs ultrasound. These methods are supplementary 
and a decision upon using one of them is based on the 
clinical setting, individual patients' needs and a meth-
ison, Lou et al.[26] found the cumulative rate of total 
antibodies and IgM was 100% on days 16 and 21, while 
the rate of IgG was 97.1% on day 29 [Table 2].
 Pan et al.[28] investigated antibody positivity both in 
COVID-19 confirmed and suspected cases and found 
the overall rate of combined IgM and IgG positive 
cases in both groups to be 68.6% (69/86) and 63.6% 
(14/22), respectively. By detecting total antibodies 
(IgM, IgG and IgA) in the first week, the diagnostics 
sensitivity ranges from 60 to 75%[24-27]. Guo et al.[23] 
point out that the detection rate of COVID-19 cases 
is only 51.9% by using a single PCR test, but signifi-
cantly increases to 98.6% when an IgM ELISA assay is 
applied to PCR-negative patients.
 When comparing the onset of seropositivity between 
anti-RBD and anti-NP, To et al.[16] found that more pa-
tients had earlier seropositivity for anti-RBD than an-
ti-NP for both IgG and IgM, while Sun et al.[25] found 
no differences between the groups. Several studies com-
pared seroconversion time and antibody titer in severe 
and non-severe patients and found no significant differ-
ence between these groups[24, 26]. Only Sun et al. found 
that S-IgG was higher in the non-intensive care unit 
(ICU) group, and N-IgG was higher in ICU group[25].
Table 2. Rates of IgM and IgG anti-SARS-CoV-2 in suspected and confirmed COVID-19 patients according to the week 
of disease and type of serological method used.
Tablica 2. Stope IgM i IgG protutijela na SARS-CoV-2 u pacijenata kod kojih se sumnja na COVID-19 infekciju ili je 
potvrđena, podijeljene prema tjednu bolesti i vrsti serološke metode.
Anti-SARS-CoV-2
Positive samples rate (%)
Week 1 Week 2 Week 3 Week 4
I
PCR confirmed cases
Total antibodies 60.0+-69.4 89.9+-94.4 100.0+ 100.0+
IgM 40.0+-58.3 75.1+-94.4 89.5-94.1+ 92.3+
IgG 55.5+-69.4 84.8+-94.4 94.7-100.0+ 100.0+
II
PCR confirmed cases
Total antibodies 64.1-75.0* 94.7*-98.7 100.0* 100.0
IgM 33.3-58.3* 84.2*-86.7 89.5* 96.7
IgG 33.3-66.7* 76.0-94.7* 100.0* 93.3
III
PCR confirmed cases
IgM 11.1 78.6 74.2 /
IgG 3.7 57.1 96.8 /
Suspected cases
IgM 22.2 33.3 57.1 /
IgG 44.4 66.7 71.4 /
I – CLIA (Chemiluminescence assay): unmarked data by Suhandynata et al. (27), + - data by Long et al. (24); 
II – ELISA (Enzyme-linked immunoassay): unmarked data by Lou et al. (26), data for weeks 3 and 4 is represented together, *- data by Sun et al. (25); 
III – ICG (Immunochromatographic assay): unmarked data by Pan et al. (28).
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age 47 ± 14 years, 48% male population) suggested COV-
ID-19, while their RT-PCR assays from throat swab sam-
ples were negative. Most patients (83%) had bilateral lung 
lesions consisting of ground-glass opacities and consoli-
dations[34].
 A possible reservoir of SARS-CoV-2 are asymp-
tomatic or oligosymptomatic patients. Several stud-
ies showed that asymptomatic cases with a history of 
exposure lead to MSCT lesions confirmed cases. The 
lung opacities on MSCT were found in 44 (54%) out of 
82 asymptomatic patients from the Cruise Ship „Di-
amond Princess”, one of the largest clusters of COV-
ID-19 patients outside China[38]. A study on asympto-
matic patients from Wuhan showed that predominant 
od’s availability. Compared to MSCT, the chest X-ray 
is a less sensitive method of detecting COVID-19 pa-
thology of the lungs. Nevertheless, it is usually the first 
imaging method performed on patients as it is a useful 
triage tool and has a role in patient’s follow-up. Just 
like the other viral pneumonias, COVID-19 pneumo-
nia causes lung opacities in more than one lobe and, 
therefore, a multi-focal air-space disease is a signifi-
cant finding. The changes such as ground-glass opac-
ities (GGO) visible on MSCT are very hard to detect 
in a CXR correlate, while the reticular opacities in the 
GGO regions are more easily detectable on a standard 
CXR[30]. A large study, performed at multiple univer-
sity clinical centres in the greater New York City area 
on 636 patients in an outpatient care setting, showed 
that the chest X-ray findings may be normal in pa-
tients with mild and moderate disease. The vast ma-
jority of patients included in this study (566/636, 89%) 
had either normal or only mildly abnormal CXRs[31]. 
The consensus for imaging published by the Fleischner 
Society states that in patients with mild clinical fea-
tures, imaging is indicated after a positive viral test if 
the patient has risk factors for disease progression. In 
patients with moderate to severe clinical features, the 
imaging is indicated after the introduction of a posi-
tive viral test if the patient is at risk of pulmonary sta-
tus worsening[32].
 The chest MSCT has an important role in detect-
ing lesions caused by SARS-CoV-2, treatment eval-
uation and patient’s follow-up. The studies on diag-
nostic MSCT from Italy and China report sensitivity 
around 97%, specificity from 25 to 56% and accuracy 
around 70%[33, 34]. The findings depend on the disease 
stage; from the first to the seventh day of the disease, 
the most common findings are ground-glass opacities 
[Figure 1], a combination of GGO and reticular pat-
tern (the „crazy-paving pattern”) [Figure 2] or GGO 
and consolidation with air bronchogram [Figure 3][35]. 
The lesions were predominantly distributed in posteri-
or and peripheral parts of the lungs bilaterally.[36] From 
the 8th to the 14th day, the lesions become denser and 
multilobular, while the progression and absorption 
signs are simultaneously present. After approximately 
fourteen days, the abnormalities start to decrease and 
repairing signs, such as bronchal distortion, subpleu-
ral line and fibrotic strips are present[37]. There seems 
to be no positive correlation between the CT find-
ings and disease severity[33]. Some parameters, such as 
blood lymphocyte count and SpO2 have shown a sta-
tistically significant negative correlation, meaning: the 
higher the CT stage, the lower the lymphocyte count 
and SpO2
[36].
 In a retrospective study by Ai et al. on a sample of 
1014 patients, the chest CT images of 308 patients (mean 
Figure 1. Thoracic multi-slice computerized tomography 
(MSCT) shows „ground glass” opacities (red square) in 
the upper left lobe in a patient with COVID-19 pneumo-
nia on the fifth day after the symptoms onset (tempera-
ture 38.6 °C and malaise).
Slika 1. Višeslojna kompjutorizirana tomografija torakal-
ne regije prikazuje zasjenjenja po tipu „mliječnog stakla” 
(crveni kvadrat) u gornjem lijevom režnju kod pacijenta s 
COVID-19 upalom pluća u petom danu nakon pojave simp-
toma (povišena tjelesna temperatura do 38.6°C i slabost).
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Figure 2. Thoracic multi-slice computerized tomography (MSCT) reveals diffuse, bilateral „crazy paving” pattern 
(red square) in a patient with COVID-19 pneumonia that started eight days earlier with a dry cough, temperature up 
to 39 °C and headache.
Slika 2. Višeslojna kompjutorizirana tomografija torakalne regije prikazuje difuzni, obostrani uzorak „ludog poplo-
čenja” (crveni kvadrat) kod pacijenta s COVID-19 pneumonijom koja je započela prije 8 dana suhim kašljem, povišenom 
tjelesnom temperaturom do 39°C i glavoboljom.
Figure 3. Thoracic multi-slice computerized tomography (MSCT) performed on the tenth day after the symptoms 
onset (temperature 38.2 °C, chest pain and shortness of breath) depicts bilateral, peripheral consolidations in lower 
lobes (red square).
Slika 3. Višeslojna kompjutorizirana tomografija torakalne regije učinjena osmi dan nakon pojave simptoma (povišena 
tjelesna temperatura do 38.2°C, bol u prsima i kratkoća daha) prikazuje obostrane, periferne konsolidacije u donjim 
režnjevima (crveni kvadrat).
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 [4] European Center for Disease Control. Laboratory support for 
COVID-19 in the EU/EEA 2020. Available at: https://www.
ecdc.europa.eu/en/novel-coronavirus/laboratory-support. Ac-
cessed on August 21 2020.
 [5] Hirotsu Y, Maejima M, Shibusawa M, et al. Comparison of Au-
tomated SARS-CoV-2 Antigen Test for COVID-19 Infection 
with Quantitative RT-PCR using 313 Nasopharyngeal Swabs 
Including from 7 Serially Followed Patients. Int J Infect Dis. 
2020;99:397-402.
 [6] Lippi G, Simundic AM, Plebani M. Potential preanalytical 
and analytical vulnerabilities in the laboratory diagnosis of 
coronavirus disease 2019 (COVID-19). Clin Chem Lab Med. 
2020;58(7):1070-1076.
 [7] Jung Y, Park GS, Moon JH, et al. Comparative analysis of prim-
er-probe sets for the laboratory confirmation of SARS-CoV-2. 
ACS Infect Dis. 2020;6,9:2513-2523.
 [8] Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic 
SARS-CoV-2 Infections and Transmission in a Skilled Nursing 
Facility. N Engl J Med. 2020;382:2081-2090.
 [9] Xiao AT, Tong YX, Gao C, Zhu L, Zhang YJ, Zhang S. Dy-
namic profile of RT-PCR findings from 301 COVID-19 pa-
tients in Wuhan, China: A descriptive study. J Clin Virol. 
2020;127:104346.
 [10] Yang Y, Yang M, Shen C, et al. Evaluating the accuracy of 
different respiratory specimens in the laboratory diagnosis 
and monitoring the viral shedding of 2019-nCoV infections. 
medRxiv. 2020. Available at: https://doi.org/10.1101/2020.02.1
1.20021493. Accessed on July 15, 2020.
 [11] Zheng S, Fan J, Yu F, et al. Viral load dynamics and disease se-
verity in patients infected with SARS-CoV-2 in Zhejiang prov-
ince, China, January-March 2020: retrospective cohort study. 
BMJ. 2020;369:m1443.
 [12] Xiao AT, Tong YX, Zhang S. Profile of RT-PCR for SARS-
CoV-2: a preliminary study from 56 COVID-19 patients. Clin 
Infect Dis. 2020;71(16):2249-2251.
 [13] Altamirano J, Govindarajan P, Blomkalns AL, et al. Assessment 
of Sensitivity and Specificity of Patient-Collected Lower Nasal 
Specimens for Sudden Acute Respiratory Syndrome Coronavi-
rus 2 Testing. JAMA Netw Open. 2020;3(6):e2012005.
 [14] Shen N, Zhu Y, Wang X, et al. Characteristics and diagnosis 
rate of 5,630 subjects receiving SARS-CoV-2 nucleic acid tests 
from Wuhan, China. JCI Insight. 2020;5(10):e137662.
 [15] Zhang JJ, Cao YY, Dong X, et al. Distinct characteristics 
of COVID-19 patients with initial rRT-PCR-positive and 
rRT-PCR-negative results for SARS-CoV-2. Allergy. 2020; 
75(7):1809-1812.
 [16] To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral 
load in posterior oropharyngeal saliva samples and serum an-
tibody responses during infection by SARS-CoV-2: an obser-
vational cohort study. Lancet Infect Dis. 2020;20(5):565-574.
 [17] Kujawski SA, Wong KK, Collins JP, et al. Clinical and virologic 
characteristics of the first 12 patients with coronavirus disease 
2019 (COVID-19) in the United States. Nat Med. 2020;26:861-
868.
 [18] Wolfel R, Corman VM, Guggemos W, et al. Virological as-
sessment of hospitalized patients with COVID-2019. Nature. 
2020;581:465-469.
 [19] Hu X, Xing Y, Jia J, et al. Factors associated with negative con-
version of viral RNA in patients hospitalized with COVID-19. 
Sci Total Environ. 2020;728:138812.
features of these cases were GGO with peripheral 
distribution, unilateral, mostly involving one or two 
lobes, combined with a subpleural curvilinear line, 
fine reticulation, air bronchogram, halo sign or vascu-
lar enlargement signs[39].
 Although RT-PCR is a fairly sensitive method of 
detecting SARS-CoV-2, there is a small percentage of 
false negative samples. This can lead to poor contain-
ment of infected individuals and uncontrolled disease 
spreading, due to the highly contagious virus nature. 
MSCT has a significant role in the diagnosis of COV-
ID-19 in these cases, particularly in the presence of 
symptoms and epidemiological exposure, ultimately 
allowing for timely isolation and proper treatment. 
The MSCT limitations are high radiation dosage com-
pared to CXR and the need for disinfection of MSCT 
machine after use, which may lead to delays in diag-
nostics and work overload in case of MSCT being the 
primary screening tool.
 The lungs ultrasound can be helpful in the evalua-
tion of patients with suspected COVID-19 infection. 
The advantages over MSCT and CXR are the conven-
ience of point of care diagnosis, no radiation and less 
utilization of personnel, such as radiologic technicians 
and transport staff. Also, it seems that the lungs ultra-
sound can detect lesions earlier if the lesions are adja-
cent to the pleura. The typical findings of COVID-19 
pneumonia are glass rockets with or without the Birol-
leau variant, confluent B lines, thick irregular pleural 
lines, and subpleural consolidations[40].
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